



**LUPIN**

December 6, 2016

**BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI**  
**(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of tentative USFDA approval for Diclofenac Capsules USP, 18 mg and 35 mg, to market a generic equivalent of Iroko Pharmaceuticals LLC's Zorvolex® Capsules 18 mg and 35 mg.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We regret the inconvenience caused to you.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**

Encl.: a.a.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

## **Lupin Receives Tentative Approval for Generic Zorvolex® Capsules**

**Mumbai, Baltimore, December 06, 2016:** Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (collectively Lupin) has received tentative approval for its Diclofenac Capsules USP, 18 mg and 35 mg from the United States Food and Drug Administration (FDA) to market a generic version of Iroko Pharmaceuticals LLC's Zorvolex® Capsules 18 mg and 35 mg.

Lupin's Diclofenac Capsules USP, 18 mg and 35 mg are the AB rated generic equivalent of Iroko Pharmaceuticals LLC's Zorvolex® Capsules 18 mg and 35 mg. It is indicated for management of mild to moderate acute pain and management of osteoarthritis pain.

Zorvolex® Capsules had US sales of USD 39.6 million (IMS MAT September 2016).

### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 6<sup>th</sup> and the 8<sup>th</sup> largest generics pharmaceutical company by market capitalization and sales globally (September 30<sup>th</sup>, 2016, Bloomberg). The Company is the 5<sup>th</sup> largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 3<sup>rd</sup> largest Indian pharmaceutical company by revenues; the 6<sup>th</sup> largest generic pharmaceutical player in Japan and the 4<sup>th</sup> largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31<sup>st</sup> March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

**For further information or queries please contact –**

Shamsher Gorawara  
Head – Corporate Communications  
Lupin Limited  
Ph: +91 98 20 338 555  
Email: [shamshergorawara@lupin.com](mailto:shamshergorawara@lupin.com)

or

## Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Arvind Bothra

Head – Investor Relations and M&A

Ph: +91-70 45 656 895

Email: arvindbothra@lupin.com

\*Safe Harbor Statement

*Zorvolex® is the registered trademark of Iroko Pharmaceuticals LLC.*